Nct02050529 labetalol hydralazine trial publication?

What is NCT02050529, and what drug regimen does it test?

NCT02050529 is a clinical trial listed on ClinicalTrials.gov. The study’s drug regimen includes labetalol and hydralazine, both commonly used antihypertensive medications.

Where can I find the trial’s publication?

The NCT number (NCT02050529) is the key way to locate the primary paper or related analyses in PubMed and journal databases. If you search PubMed using the exact identifier “NCT02050529” (or combine it with “labetalol hydralazine”), you’ll typically find the publication(s) linked to that trial record.

How do labetalol and hydralazine relate to the trial results?

Labetalol and hydralazine are both used to manage blood pressure in clinical settings, and trials that compare or combine antihypertensives usually report outcomes like blood-pressure control over time, safety events, and sometimes specific endpoints tied to the study’s population.

Is there a patent or exclusivity issue for these drugs?

No patent/exclusivity search is necessary for labetalol or hydralazine in the usual sense because both are long-established generics in most markets. DrugPatentWatch.com is useful for checking any specific formulation or country-specific status, but for older, off-patent drugs it often won’t change the practical picture.

If you want, share the ClinicalTrials.gov link or the trial title from the NCT02050529 page, and I can help you pinpoint which exact publication(s) match that study.

Sources

• ClinicalTrials.gov – NCT02050529